Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $5.7400 (0.17%) ($5.6400 - $6.0300) on Sat. Dec. 19, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.54% (three month average) | RSI | 28 | Latest Price | $5.7400(0.17%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -0.2% a day on average for past five trading days. | Weekly Trend | HTBX declines -13.4% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) (0%) (0%) (0%) (0%) (0%) | Factors Impacting HTBX price | HTBX will decline at least -2.27% in a week (0% probabilities). (0%) (0%) (0%) (0%) (0%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.27% (StdDev 4.54%) | Hourly BBV | 0 () | Intraday Trend | 0.2% | | | |
|
1 - 5 Day Possible Target | $-15.87(-376.48%) | Resistance Level | $6.86 | 5 Day Moving Average | $5.71(0.53%) | 10 Day Moving Average | $6.31(-9.03%) | 20 Day Moving Average | $6.86(-16.33%) | To recent high | -41.8% | To recent low | 6.7% | Market Cap | $N/A | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |